Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series

被引：0
|
作者：
Hua, Y. [1 ]
Xu, W. [1 ]
Shi, H. [1 ]
Zheng, X. [1 ]
Li, X. [1 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
基金：
北京市自然科学基金;
关键词：
NSCLC; MET; savolitinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12D.07
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [2] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [3] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [4] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [5] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [6] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
    Nishio, Makoto
    Kato, Terufumi
    Niho, Seiji
    Yamamoto, Noboru
    Takahashi, Toshiaki
    Nogami, Naoyuki
    Kaneda, Hiroyasu
    Fujita, Yuka
    Wilner, Keith
    Yoshida, Mizuki
    Isozaki, Mitsuhiro
    Wada, Shinsuke
    Tsuji, Fumito
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2020, 111 (05) : 1724 - 1738
  • [7] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
    Merimsky, Ofer
    Cheng, Chi-Kin
    Au, Joseph Siu-Kie
    Von Pawel, Joachim
    Reck, Martin
    ONCOLOGY REPORTS, 2012, 28 (02) : 721 - 727
  • [8] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [9] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [10] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
12345